Internationally renowned ophthalmologist and investment leader joins to support advancement of disruptive ophthalmic treatmentsSAN CARLOS, Calif., May 3, 2024 /PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today the appointment of Dr.

国际著名眼科医生和投资领袖加入支持颠覆性眼科治疗的进展加利福尼亚州萨恩·卡洛斯，2024年5月3日/新闻专线/--引领眼科治疗创新的下一代生物制药公司RevOpsis Therapeutics今天宣布任命Dr。

Emmett Cunningham to its Strategic Advisory Board (SAB) and as a private investor. Dr. Cunningham, a distinguished figure in the ophthalmic and investment communities, brings more than twenty years of experience as a full-time entrepreneur and investor to his new role with RevOpsis..

埃米特·坎宁安（EmmettCunningham）加入其战略咨询委员会（SAB），并成为私人投资者。坎宁安博士是眼科和投资界的杰出人物，他在RevOpsis担任新角色时，拥有20多年的全职企业家和投资者经验。。

Continue Reading

继续阅读

'I am honored to join RevOpsis as an early investor and Strategic Advisory Board member.' said Dr. Emmett Cunningham.

“我很荣幸以早期投资者和战略咨询委员会成员的身份加入RevOpsis。”埃米特·坎宁安博士说。

Post this

发布此

Dr. Emmett Cunningham, RevOpsis Strategic Advisory Board member

Emmett Cunningham博士，RevOpsis战略咨询委员会成员

Dr. Cunningham is currently Senior Partner at HealthQuest Capital Management. Prior, he most recently served as a Senior Managing Director at Blackstone Life Sciences group (BXLS) of Blackstone, Inc. (BX), through the acquisition of Clarus Ventures in 2018, where he was a member of the full-time investment team since Clarus' inception in 2006..

坎宁安博士目前是HealthQuest资本管理公司的高级合伙人。在此之前，他最近通过2018年收购Clarus Ventures担任黑石生命科学集团（BXLS）的高级常务董事，自Clarus 2006年成立以来，他一直是全职投资团队的成员。。

'I am honored to join RevOpsis as an early investor and Strategic Advisory Board member. My experience is well aligned to contribute to the RevOpsis mission of revolutionizing ophthalmic therapies,' said Dr. Emmett Cunningham. 'I am impressed by the company's dedication to innovation and commitment to improving patient care.

“我很荣幸以早期投资者和战略咨询委员会成员的身份加入RevOpsis。埃米特·坎宁安（EmmettCunningham）博士说，我的经验与RevOpsis眼科治疗革命的使命是一致的公司致力于创新，致力于改善患者护理，给我留下了深刻的印象。

I look forward to collaborating with the team to drive their pipeline of transformative treatments forward.'.

我期待着与团队合作，推动他们的变革性治疗管道向前发展。”。

With a career spanning notable roles at leading investment firms, Dr. Cunningham's expertise in guiding successful investments in biotechnology companies is unparalleled. His track record includes significant contributions to the development and FDA approval of ten therapeutics, with an additional therapeutic pending FDA submission.His visionary leadership and strategic insights have played a pivotal role in shaping the landscape of ophthalmic therapies, driving innovation, and fostering growth within the industry.

坎宁安博士在领先的投资公司担任了重要的职位，在指导生物技术公司成功投资方面拥有无与伦比的专业知识。他的业绩记录包括对十种治疗药物的开发和FDA批准做出了重大贡献，另外还有一种治疗药物有待FDA提交。他的远见卓识和战略见解在塑造眼科治疗的格局、推动创新和促进行业增长方面发挥了关键作用。

Dr. Cunningham's prestigious career includes several prominent board memberships with various noteworthy biopharmaceutical companies including several ophthalmology focused companies such as Annexon Biosciences, GrayBug Vision, Nacuity Pharmaceuticals, and Eyconis, where he is co-founder and executive chair.'We are excited to welcome Dr.

坎宁安博士享有盛誉的职业生涯包括在多家值得注意的生物制药公司担任董事会成员，其中包括Annexon Biosciences、GrayBug Vision、Nacity Pharmaceuticals和Eyconis等几家专注眼科的公司，他是这些公司的联合创始人和执行主席我们很高兴欢迎博士。

Emmett Cunningham to our Strategic Advisory Board,' said RevOpsis interim CEO Dr. Ram Bhandari. 'Dr. Cunningham's wealth of experience and deep understanding of the ophthalmic and investment landscapes make him an invaluable asset to the RevOpsis SAB. Dr. Cunningham's guidance will be instrumental as we continue to advance our proprietary Rev-Mod Platform and develop novel treatments for chronic multifactorial diseases, including our current lead candidate RO-104.'In addition to his remarkable achievements in the investment sector, Dr.

RevOpsis临时首席执行官拉姆·班达里（RamBhandari）博士说，埃米特·坎宁安（EmmettCunningham）向我们的战略咨询委员会致辞。坎宁安博士丰富的经验以及对眼科和投资领域的深刻理解，使他成为RevOpsis SAB的宝贵资产。坎宁安博士的指导将有助于我们继续推进专有的Rev Mod平台，并开发针对慢性多因素疾病的新型治疗方法，包括我们目前的主要候选人RO-104。”。

Cunningham is widely recognized as an internationally renowned specialist in infectious and inflammatory eye diseases. He has authored over 400 publications and made significant contributions to advancing the understanding and treatment of vision-related disorders.About RO-104Leveraging the proprietary Rev-Mod platform, RO-104 is RevOpsis' current lead candidate.

坎宁安是国际公认的传染性和炎性眼病专家。他撰写了400多篇出版物，为促进对视力相关疾病的理解和治疗做出了重大贡献。关于RO-104利用专有的Rev Mod平台，RO-104是RevOpsis目前的主要候选人。

Engineered as a first-in-class .

一流的设计。